On March 18, 2026 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC)
Type: Oral Presentation
Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms
Date and Time: Sunday, April 19, 4:05-4:20 p.m. PT
Abstract Number: 1325
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics

Title: EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2
Type: Poster Presentation
Session: Clinical Research 1
Date and Time: Sunday, April 19, 2-5 p.m. PT
Abstract Number: LB012
Lead Author: Markus Eckstein, M.D., University Hospital Erlangen (FAU Erlangen -Nürnberg)

Title: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: results from a Phase 1/2 study
Type: Poster Presentation
Session: First-in-Human Phase I Clinical Trials
Date and Time: Monday, April 20, 9 a.m.-12 p.m. PT
Abstract Number: CT063
Lead Author: Babar Bashir, M.D., Thomas Jefferson University

Title: Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC)
Type: Poster Presentation
Session: Hematologic Malignancies and Novel Therapeutic Modalities
Date and Time: Tuesday, April 21, 9 a.m.-12 p.m. PT
Abstract Number: 4518
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics

Title: Development and first clinical experiences of a phage display derived bicyclic peptide for EphA2-specific PET imaging
Type: Poster Presentation
Session: Diagnostic Biomarkers 2
Date and Time: Tuesday, April 21, 2-5 p.m. PT
Abstract Number: 6520
Lead Author: Ann-Christin Eder, Ph.D., University of Freiberg and German Cancer Consortium (DKTK)

The presentations will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session.

(Press release, Bicycle Therapeutics, MAR 18, 2026, View Source [SID1234663696])

On March 18, 2026 Amphista Therapeutics Ltd. (the "Company" or "Amphista"), a leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, reported the appointment of Louise Modis, Ph.D., as its Chief Executive Officer (CEO) and member of the Board of Directors, and Patrick Kelly M.D. as its Chief Medical Officer (CMO). Dr. Modis succeeds Antony Mattessich who is retiring.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Modis joined Amphista in May 2023 as Chief Scientific Officer. She is an accomplished leader who brings a combination of deep scientific expertise and strategic focus to the role, gained from over two decades of experience advancing innovative medicines into the clinic across biotech and pharma. She has been instrumental in driving Amphista’s progress to date, having defined the Company’s R&D strategy and building its strong pipeline. Dr. Modis will continue to provide scientific leadership while guiding the Company’s strategic direction.

Dr. Kelly joins Amphista and strengthens the clinical leadership as the Company enters the clinic with AMX-883 in acute myeloid leukemia (AML). He brings 35 years of clinical research and clinical practice experience, most recently serving as CMO at Forma Therapeutics where he led the development of olutasidenib, which is now approved for the treatment of IDH1-mutated AML. Dr. Kelly will play a pivotal role in leading the clinical development team and shaping Amphista’s development strategy across the pipeline.

Joshua Brumm, Chairman of Amphista’s Board of Directors said: "The Board is delighted to announce the appointments of Louise as CEO and Patrick as CMO. We have been impressed with Louise’s vision and execution of Amphista’s science strategy, and her appointment reflects our confidence in her leadership as we transition to be a clinical-stage company. Combined with Patrick’s clinical expertise, Amphista is well positioned to successfully deliver our differentiated pipeline to patients. On behalf of the Board, I would also like to thank Antony for his contributions and wish him the best in his retirement."

Louise Modis, Chief Executive Officer of Amphista, commented: "I’m honored to lead Amphista. As CEO, my priority is to ensure we deliver clinical excellence for AMX-883 and to accelerate our earlier programs into the clinic. With the addition of Patrick as CMO, and the strength of our leadership team, we are well positioned to execute our clinical strategy and advance our BRD9, SMARCA, and TEAD programs for patients and their families."

Patrick Kelly, Chief Medical Officer of Amphista, commented, "I am excited to join Amphista as the Company prepares to enter the clinic with AMX-883 on the back of impressive pre-clinical data. I look forward to working with Louise and the team to deliver the AMX-883 clinical program in AML and building a robust clinical strategy across the broader pipeline."

As a karyotype-independent, pro-differentiation agent, AMX-883 has the potential to transform the treatment paradigm for AML. Amphista expects to submit the Investigational New Drug application to the US Food and Drug Administration for AMX-883 in April and to start its clinical trial in H2 2026.

Amphista is developing potent, selective, orally bioavailable degraders of SMARCA2 and TEAD. The Company remains on track to deliver a shortlist of best-in-class compounds later this year for further profiling ahead of candidate nomination.

(Press release, Amphista Therapeutics, MAR 18, 2026, View Source [SID1234663695])

On March 18, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported that new data from a Phase 1 investigator‑initiated trial (IIT) evaluating intratumoral mitazalimab administered in conjunction with irreversible electroporation (IRE) in locally advanced pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. The meeting takes place between 17-22 April 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract details
Title: Irreversible electroporation (IRE) with intratumoral CD40 antibody increases T cell reactivity to personalized neoantigens in locally advanced pancreatic cancer
Time: Monday, 20 April 2026, 09:00 am – 12:00 pm PDT
Session: PO.CTP01.01 – Phase I Clinical Trials in Progress, Section 51
Presenter: Dr. Rebekah R. White, UC San Diego School of Medicine, La Jolla, CA

The accepted abstract will be made available on 17 April at aacr.org.

(Press release, Alligator Bioscience, MAR 18, 2026, View Source [SID1234663694])

On March 18, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, reported its abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, being held April 17–22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:
Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast
Poster Number: 3179
Poster Board Number: 14
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
Date and Time: Monday, April 20, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 19

The poster presented at the conference will be available for review on the Posters & Publications page on the Company’s website on April 20, 2026 after 5:00 PM PT.

Parties interested in meeting with the Akari team at the conference can direct inquires to [email protected].

For more information about the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, please visit aacr.org.

(Press release, Akari Therapeutics, MAR 18, 2026, View Source [SID1234663693])

On March 18, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad and encompass multiple cancer types – including pancreatic cancer. AIM also holds a U.S. patent (expires August 9, 2039) for methods involving the use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab).

AIM CEO Thomas K. Equels stated: "AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy."

AIM also intends to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer. The Company already holds Orphan Drug designations for pancreatic cancer in the United States and the European Union. While the details of the designations vary by region, the purpose is to incentivize the development of therapies for unmet health needs, by providing various benefits and market exclusivity after a drug receives market approval.

(Press release, AIM ImmunoTech, MAR 18, 2026, View Source [SID1234663692])